title: NF-kappaB inhibition in EBV-transformed lymphoblastoid cell lines.
abstract: Epstein-Barr virus (EBV) transforms B-lymphocytes into lymphoblastoid cell lines usurping multiple signaling pathways including NF-kappaB activation. To determine whether NF-kappaB activity is essential in the growth and survival of EBV-transformed lymphoblastoid cell lines, a non-degradable IkappaBa mutant was expressed under tetracycline regulation in IB4 cells. NF-kappaB inhibition caused caspase 3 and 8 activation, PARP cleavage, and DNA fragmentation indicative of apoptosis. Mitochondrial membrane potential was diminished without release of cytochrome c or apoptosis initiating factor. z-VAD.FMK, a general caspase inhibitor, failed to block apoptosis, indicating a distinct pathway contributes to cell death. Bfl-1 expression, an anti-apoptotic Bcl-2 family member, is diminished after NF-kappaB inhibition whereas Bcl-2 and Bcl-x/L expression is unaffected. These studies suggest that NF-kappaB itself, or NF-kappaB-regulated genes, will be successful molecular targets for the treatment of EBV-associated diseases.
authors.affiliation: Department of Infectious Diseases and the Channing Laboratory, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: Ellen
authors.initials: E
authors.lastname: Cahir-McFarland
authors.forename: Elliott
authors.initials: E
authors.lastname: Kieff
mesh_terms: D001402:B-Lymphocytes / Q000821:virology; D002461:Cell Line, Transformed / Q000378:metabolism*; D002470:Cell Survival; D002472:Cell Transformation, Viral; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D016328:NF-kappa B